# Mekonos

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mekonos

- Industry: Healthcare
- Headquarters: San Francisco, US
- Website: www.mekonos.com
- Total disclosed funding: $31M
- Latest round: Series A (Oct 14, 2021)
- Investors on record: 13

## About

Mekonos Inc. specializes in precision gene engineering through its advanced microfluidic technology, aiming to provide integrated solutions for biopharmaceutical applications and enhance therapeutic development.Founded in 2017 and headquartered in San Francisco, US, Mekonos Inc. focuses on developing a proprietary system-on-a-chip (SoC) for targeted ex vivo gene engineering. The company has conducted 4 deals, with the most recent funding round occurring on October 14, 2021. The Series A funding raised USD 24.98 mn, with involvement from a variety of investors including Fiscus Ventures, PEAK6 Investments, and Novartis International AG. The company was co-founded by Anil Narasimha, Greg Sitters, and Steven Banerjee, with Anil Narasimha also serving as the CEO.Mekonos Inc. offers advanced microfluidic systems designed to facilitate precise gene editing and biological research. Their technology enables efficient manipulation of biological samples at the microscale, catering to pharmaceutical companies and research institutions aiming to enhance their gene therapy pipelines. The company’s solutions are intended to promote efficiency in biopharmaceutical drug development by integrating various functions into a cohesive platform, thereby streamlining workflows for researchers and developers in the field.Mekonos Inc. generates revenue primarily through partnerships and collaborations with biopharmaceutical companies, leveraging its innovative technology for research and development purposes. The revenue model is structured to support diverse client requirements, with tailored solutions to enhance gene engineering processes and therapeutic advancements.Following their Series A funding of USD 24.98 mn in October 2021, Mekonos Inc. plans to accelerate the development of its MEMS and microfluidics capabilities, alongside its business development function. The funding will support the advancement of its integrated system-on-a-chip (SoC) for targeted ex vivo gene engineering, expansion of commercial partnerships, and talent acquisition. The company is also focused on entering new markets within the biopharmaceutical sector, specifically targeting regions in North America and Europe for strategic growth initiatives.

## Funding rounds

- Series A, Oct 14, 2021, $25M — PEAK6 Investments, Novartis International AG, Sands Capital Alternatives, Elementum Ventures, Section 32, Qstar Capital, Debiopharm Innovation Fund, TDK Ventures, Fiscus Ventures
- Seed, Nov 23, 2020, $4.6M — CRCM, Novartis International AG, Elementum Ventures, Good AI Capital, Hike Ventures
- Seed, Jan 10, 2019 — Matu Fund
- Seed, Jun 4, 2018, $1.4M — Novartis International AG, Elementum Ventures, Good AI Capital

## Investors

- Novartis International AG — Seed, Series A
- Elementum Ventures (https://capitalatlas.ai/funds/elementum-ventures) — Seed, Series A
- Good AI Capital (https://capitalatlas.ai/funds/good-ai-capital) — Seed
- Matu Fund (https://capitalatlas.ai/funds/matu-fund) — Seed
- CRCM (https://capitalatlas.ai/funds/crcm) — Seed
- Hike Ventures — Seed
- PEAK6 Investments (https://capitalatlas.ai/funds/peak6-investments) — Series A
- Sands Capital Alternatives (https://capitalatlas.ai/funds/sands-capital-alternatives) — Series A
- Section 32 (https://capitalatlas.ai/funds/section-32) — Series A
- Qstar Capital (https://capitalatlas.ai/funds/qstar-capital) — Series A
- Debiopharm Innovation Fund (https://capitalatlas.ai/funds/debiopharm-innovation-fund) — Series A
- TDK Ventures (https://capitalatlas.ai/funds/tdk-ventures) — Series A
- Fiscus Ventures — Series A